

Electronic Supporting Information

Enhanced antitumoral activity when combining PARP inhibitors with encapsulated BET inhibitors for the treatment of BRCA-mutated cancers

Alberto Juan,^{1#} María del Mar Noblejas-López,^{1,2#} Iván Bravo,^{1,2} María Arenas-Moreira,^{1,2} Cristina Blasco-Navarro,² Pilar Clemente-Casares,^{1,2} Agustín Lara-Sánchez,³ Atanasio Pandiella,⁴ Carlos Alonso-Moreno^{1,2*} and Alberto Ocaña^{5*}

¹Centro Regional de Investigaciones Biomédicas (CRIB), UCLM, Albacete-02008, Spain

²Translational Oncology Laboratory, Translational Research Unit, Albacete University Hospital, Albacete-02008, Spain

³Universidad de Castilla-La Mancha. Facultad de Farmacia de Albacete, Albacete-02008, Spain

⁴Universidad de Castilla-La Mancha. Facultad de Ciencias y Tecnologías Químicas, Ciudad Real-13005, Spain

⁵Centro de Investigación del Cáncer-CSIC. IBSAL- Salamanca and CIBERONC, Salamanca-37007, Spain

⁶Experimental Therapeutics Unit, Hospital clínico San Carlos, IdISSC and CIBERONC, Madrid-28040, Spain

[#]Both authors contributed equally

(*) corresponding authors:

Carlos Alonso-Moreno, PhD. Unidad nanoCRIB, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, 02008 Albacete, Spain. E-mail: Carlos.amoreno@uclm.es. Phone number: +34967599200

Alberto Ocaña, PhD. Experimental Therapeutics Unit, Hospital clínico San Carlos, IdISSC and CIBERONC, Madrid, Spain. Email: alberto.ocana@salud.madrid.org. Phone number: +34 635681806.



A**B**

Figure S1. **A.** JQ1 free and JQ1-encapsulated forms synergize with olaparib in breast cancer cells MDA-MB-231. Dot plot represent percentage of cells Annexin V positive/negative and Propidium Iodide positive/negative after each treatment (400 nM). * $p \leq 0.05$; ** $p \leq 0.01$ and *** $p \leq 0.001$. **B.** JQ1 free and JQ1-encapsulated forms synergize with olaparib in ovarian cancer cells OVCAR8. Dot plot represent percentage of cells Annexin V positive/negative and Propidium Iodide positive/negative after each treatment (400 nM). * $p \leq 0.05$; ** $p \leq 0.01$ and *** $p \leq 0.001$.